View in EDS

Synthetic chemistry enabling the discovery and development of a series of pyrazoles as HPK1 inhibitors.

Saved in:
Bibliographic Details
Title: Synthetic chemistry enabling the discovery and development of a series of pyrazoles as HPK1 inhibitors.
Authors: Metrano AJ; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com., Morrill LA; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com., Bommakanti G; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com., Casella R; Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca Waltham MA 02451 USA., Cook S; Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca Waltham MA 02451 USA., Escobar RA; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com., Giblin KA; Oncology R&D, AstraZeneca Cambridge CB2 0AA UK., Gosselin E; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com., Grebe T; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com., Hariparsad N; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com., Howells R; Oncology R&D, AstraZeneca Cambridge CB2 0AA UK., Lamont GM; Oncology R&D, AstraZeneca Cambridge CB2 0AA UK., Mele DA; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com., Pflug A; Discovery Sciences, R&D, AstraZeneca Cambridge CB2 0AA UK., Proia TA; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com., Rezaei H; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com., Richter M; Discovery Sciences, R&D, AstraZeneca Cambridge CB2 0AA UK., Richards R; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com., San Martin M; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com., Schimpl M; Discovery Sciences, R&D, AstraZeneca Cambridge CB2 0AA UK., Schuller AG; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com., Sha L; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com., Sheppeck JE 2nd; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com., Song K; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com., Tang H; Discovery Sciences, R&D, AstraZeneca Cambridge CB2 0AA UK., Wagner DJ; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com., Wang J; Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca Waltham MA 02451 USA., Wu A; Discovery Sciences, R&D, AstraZeneca Waltham MA 02451 USA., Wu D; Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca Waltham MA 02451 USA., Wu Y; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com., Xu K; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com., Ye M; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com., Shields JD; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com., Grimster NP; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com.
Source: RSC medicinal chemistry [RSC Med Chem] 2025 May 27; Vol. 16 (8), pp. 3522-3529. Date of Electronic Publication: 2025 May 27 (Print Publication: 2025).
Publication Type: Journal Article
Journal Info: Publisher: Royal Society of Chemistry Country of Publication: England NLM ID: 101759460 Publication Model: eCollection Cited Medium: Internet ISSN: 2632-8682 (Electronic) Linking ISSN: 26328682 NLM ISO Abbreviation: RSC Med Chem Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2632-8682
DOI:10.1039/d5md00309a